ESMO 2021: Pembrolizumab as monotherapy for first-line treatment of non-clear cell kidney cancer
Non-clear cell RCC is about 20-25% of all RCC diagnoses [...]
ESMO 2021: Pembrolizumab as monotherapy for first-line treatment of kidney cancer
KEYNOTE-427 is an open-label, single-arm, phase II study to look [...]
ESMO 2021: Pembrolizumab as adjuvant therapy
Adjuvant therapy is medication that is given in addition to [...]
Health-related quality of life for kidney cancer patients on pembrolizumab/lenvatinib
In this video, Dr Bradley McGregor from the Dana-Farber Cancer [...]
FDA approves pembrolizumab plus lenvatinib combination for advanced kidney cancer
The US Food and Drug Administration (FDA) has approved the [...]
Lenvatinib plus pembrolizumab in for untreated and previously treated metastatic kidney cancer
Results from a phase Ib/II study looking at lenvatinib plus [...]
ASCO 2021: Pembrolizumab plus axitinib continues to improve survival in kidney cancer
The KEYNOTE-426 study of the immune checkpoint inhibitor, pembrolizumab plus [...]
ASCO 2021: Health-related quality of life for lenvatinib plus pembrolizumab for advanced kidney cancer
Results from the phase 3 CLEAR study were presented at [...]
ASCO 2021: Pembrolizumab as adjuvant therapy for kidney cancer
Adjuvant therapy is medication that is given in addition to [...]
Adjuvant pembrolizumab extends disease-free survival in kidney cancer patients
Interim results from a phase 3 clinical trial called KEYNOTE-564 [...]
